Mittendorf and colleagues have described the loss of HER2 amplification in residual disease in 32% of BC patients treated with neoadjuvant trastuzumab in combination with anthracyclines and taxanes, as this change is associated with poor recurrence-free survival (43). Here, ERBB2 is linked to breast cancer.